Purdue's $8.3bn Settlement With DOJ Requires Reconstitution As Public Benefit Company
Executive Summary
Purdue pleads guilty to three felony charges over marketing of OxyContin under settlement that requires Purdue to be dissolved and transformed into an entity that provides addiction and overdose medicines. Twenty-five state AGs oppose creation of a PBC, arguing Purdue should be sold to another company.
You may also be interested in...
Purdue Proposes Generic Overdose Treatments Under Reorganization Plan
Purdue Pharma has laid out details of a reorganization plan “unprecedented in scope and nature,” which it says would transfer billions of dollars of value into trusts “for the benefit of the American people.”
Infographic: A Decade Of Opioid Lawsuits And Settlements
A timeline of the history of opioid litigation from Purdue Pharma's 2007 settlement to the bellwether trial in Ohio.
Will Purdue Bankruptcy Filing Resolve 'Unrelenting Chaos' Of Opioid Litigation?
Filing stays litigation but state attorneys general will be battling company's settlement proposal in US bankruptcy court. Details emerge on Purdue finances, rebate expenditures and litigation costs.